Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2023-04-18 Investor Presentation
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
Investor Presentation Classification · 98% confidence The document text is a detailed presentation summarizing clinical trial results (Phase 2 data readout for VB10.16), including executive summaries, safety data, pipeline overview, and trial methodology (VB C-02 trial details). This format, rich with scientific data, tables, charts, and strategic updates, is characteristic of an Investor Presentation (IP) or a presentation given at an investor/scientific conference. It is not a formal regulatory filing like a 10-K, a short earnings release (ER), or a formal Audit Report (AR). Given the comprehensive nature of the clinical data presentation aimed at investors and analysts, the most appropriate classification is Investor Presentation (IP). The document length is substantial (over 31k characters), confirming it is the primary content, not just an announcement (RPA/RNS).
2023-04-18 English
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
Regulatory Filings Classification · 95% confidence The document is an announcement from Nykode Therapeutics detailing the positive final results from a Phase 2 clinical trial (VB-C-02) for their drug candidate VB10.16. It provides key efficacy and safety data (median overall survival, progression-free survival, response rates) and outlines future plans, including initiating a potentially registrational trial. This content aligns perfectly with an Earnings Release (ER), which typically announces key periodical financial or operational results, or an Interim/Quarterly Report (IR) if it were a comprehensive report. Since this is a specific announcement of trial results, which often accompanies or precedes a formal earnings report, it fits best under the 'Earnings Release' category, as it communicates the most critical operational performance update for the period. It is not a full 10-K, an investor presentation (IP), or a management discussion (MDA), but rather the headline announcement of results.
2023-04-18 English
Nykode Therapeutics - Quarterly report 4Q 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and explicitly covers the '4th Quarter 2022' financial results for Nykode Therapeutics ASA. It contains detailed financial statements, including an income statement, key financial figures, and a comprehensive management review of business operations and R&D updates. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q4 2022
2023-02-28 English
Nykode Therapeutics - Quarterly report 4Q 2022
Earnings Release Classification · 95% confidence The document explicitly states it is announcing the 'unaudited financial results for the fourth quarter of 2022' for Nykode Therapeutics. This indicates an announcement of periodic financial results, which aligns with the Earnings Release (ER) definition. However, the document is very short (2723 characters) and directs the reader to a link to access the full 'financial report'. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement pointing to the full report suggests this document is the announcement itself, not the comprehensive report. Since it is a quarterly result announcement, it fits the Earnings Release (ER) category better than the general Regulatory Filing (RNS) or Report Publication Announcement (RPA), as ER is specifically for periodical financial result announcements. Given the context of quarterly results, ER is the most precise fit, even if it functions as an announcement. Q4 2022
2023-02-28 English
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023
Report Publication Announcement Classification · 98% confidence The document is a short announcement titled "Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023." It explicitly states *when* the financial results will be reported and *when* the associated webcast presentation will occur. This is not the full financial report (10-K or IR) nor the initial release of the results (ER), but rather an announcement about the future release date and event details. According to Rule 2, if a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2023-02-22 English
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023
Report Publication Announcement Classification · 98% confidence The document is a short press release announcing the date and time for the release of the Q4 2022 financial results and a subsequent webcast presentation. It explicitly states: 'Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023'. Since the document is short (3048 chars) and its primary function is to announce the publication of a future report/event rather than containing the full report or detailed results itself, it fits the definition of a Report Publication Announcement (RPA). It is not the Earnings Release (ER) itself, which would contain the actual Q4 figures.
2023-02-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.